- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00979420
Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune
Обзор исследования
Статус
Условия
Подробное описание
Study Design:
observational
Тип исследования
Контакты и местонахождение
Места учебы
-
-
-
Aachen, Германия
- Boehringer Ingelheim Investigational Site 1
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 10
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 11
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 14
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 4
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 5
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 8
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 9
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 12
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 13
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 15
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 2
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 3
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 6
-
Berlin, Германия
- Boehringer Ingelheim Investigational Site 7
-
Bochum, Германия
- Boehringer Ingelheim Investigational Site 16
-
Bonn, Германия
- Boehringer Ingelheim Investigational Site 17
-
Bremen, Германия
- Boehringer Ingelheim Investigational Site 18
-
Dortmund, Германия
- Boehringer Ingelheim Investigational Site 19
-
Duisburg, Германия
- Boehringer Ingelheim Investigational Site 20
-
Düsseldorf, Германия
- Boehringer Ingelheim Investigational Site 21
-
Düsseldorf, Германия
- Boehringer Ingelheim Investigational Site 22
-
Düsseldorf, Германия
- Boehringer Ingelheim Investigational Site 23
-
Düsseldorf, Германия
- Boehringer Ingelheim Investigational Site 24
-
Frankfurt, Германия
- Boehringer Ingelheim Investigational Site 25
-
Frankfurt, Германия
- Boehringer Ingelheim Investigational Site 26
-
Frankfurt, Германия
- Boehringer Ingelheim Investigational Site 27
-
Freiburg, Германия
- Boehringer Ingelheim Investigational Site 28
-
Freiburg, Германия
- Boehringer Ingelheim Investigational Site 29
-
Freiburg, Германия
- Boehringer Ingelheim Investigational Site 30
-
Hamburg, Германия
- Boehringer Ingelheim Investigational Site 31
-
Hamburg, Германия
- Boehringer Ingelheim Investigational Site 32
-
Hamburg, Германия
- Boehringer Ingelheim Investigational Site 33
-
Hamburg, Германия
- Boehringer Ingelheim Investigational Site 34
-
Hamburg, Германия
- Boehringer Ingelheim Investigational Site 35
-
Hamburg, Германия
- Boehringer Ingelheim Investigational Site 36
-
Hannover, Германия
- Boehringer Ingelheim Investigational Site 37
-
Hannover, Германия
- Boehringer Ingelheim Investigational Site 38
-
Hannover, Германия
- Boehringer Ingelheim Investigational Site 39
-
Heidelberg, Германия
- Boehringer Ingelheim Investigational Site 40
-
Karlsruhe, Германия
- Boehringer Ingelheim Investigational Site 41
-
Koblenz, Германия
- Boehringer Ingelheim Investigational Site 42
-
Leipzig, Германия
- Boehringer Ingelheim Investigational Site 43
-
Mannheim, Германия
- Boehringer Ingelheim Investigational Site 44
-
Mannheim, Германия
- Boehringer Ingelheim Investigational Site 45
-
München, Германия
- Boehringer Ingelheim Investigational Site 46
-
München, Германия
- Boehringer Ingelheim Investigational Site 47
-
München, Германия
- Boehringer Ingelheim Investigational Site 48
-
München, Германия
- Boehringer Ingelheim Investigational Site 49
-
München, Германия
- Boehringer Ingelheim Investigational Site 50
-
Münster, Германия
- Boehringer Ingelheim Investigational Site 51
-
Münster, Германия
- Boehringer Ingelheim Investigational Site 52
-
Münster, Германия
- Boehringer Ingelheim Investigational Site 53
-
Oldenburg, Германия
- Boehringer Ingelheim Investigational Site 54
-
Osnabrück, Германия
- Boehringer Ingelheim Investigational Site 55
-
Saarbrücken, Германия
- Boehringer Ingelheim Investigational Site 56
-
Stuttgart, Германия
- Boehringer Ingelheim Investigational Site 57
-
Stuttgart, Германия
- Boehringer Ingelheim Investigational Site 58
-
Stuttgart, Германия
- Boehringer Ingelheim Investigational Site 59
-
Wuppertal, Германия
- Boehringer Ingelheim Investigational Site 60
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Описание
Inclusion criteria The inclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843)
Exclusion criteria The exclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843).
Учебный план
Как устроено исследование?
Детали дизайна
- Временные перспективы: Ретроспектива
Когорты и вмешательства
Группа / когорта |
---|
Лечение ВИЧ
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Change in log10 Viral Load From Baseline to Last Visit
Временное ограничение: Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Baseline is defined as the last documentation before start of therapy with Viramune.
The change from baseline reflects the last available visit viral load minus the baseline viral load.
|
Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Number of Participants With Viral Load <50 Copies/ml and >=50 Copies/ml at Last Visit
Временное ограничение: Last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
|
Change in Absolute CD4 Lymphocytes (CD4+) Cells From Baseline to Last Visit
Временное ограничение: Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Baseline is defined as the last documentation before start of therapy with Viramune.
The change from baseline reflects the last available number of CD4+ cells minus the baseline number of CD4+ cells.
|
Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Change in Absolute CD4 Lymphocytes (CD4+ Cells) From Baseline to Last Visit
Временное ограничение: Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Baseline is defined as the last documentation before start of therapy with Viramune.
The change from baseline reflects the last available number of CD4+ cells minus the baseline number of CD4+ cells.
|
Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Number of Patients With Laboratory Abnormalities for Cholesterol During Study (Worst Grade) by Division of AIDS (DAIDS) Grade
Временное ограничение: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events ("DAIDS AE Grading Table") was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Low-density Lipoprotein (LDL) Cholesterol During Study (Worst Grade) by DAIDS Grade
Временное ограничение: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Triglycerides During Study (Worst Grade) by DAIDS Grade
Временное ограничение: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Blood Glucose During Study (Worst Grade) by DAIDS Grade
Временное ограничение: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Alanine Aminotransferase (ALT) During Study (Worst Grade) by DAIDS Grade
Временное ограничение: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Aspartate Aminotransferase (AST) During Study (Worst Grade) by DAIDS Grade
Временное ограничение: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Creatinine During Study (Worst Grade) by DAIDS Grade
Временное ограничение: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Hemoglobin During Study (Worst Grade) by DAIDS Grade
Временное ограничение: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Duration of Intake of Viramune
Временное ограничение: End of treatment, up to 185 months
|
Duration of intake of Viramune
|
End of treatment, up to 185 months
|
History of Therapy With Antiretroviral Medication
Временное ограничение: Baseline
|
Participants with a history of therapy with antiretroviral medication.
|
Baseline
|
Course of Absolute CD4+ Cell Count
Временное ограничение: Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months
|
The course of absolute CD4+ cell count is presented as the absolute CD4+ cell count at last visit.
|
Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months
|
Number of Participants With Drug Related Adverse Events
Временное ограничение: Up to 185 months
|
Number of participants with drug related Adverse Events (AEs)
|
Up to 185 months
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- РНК-вирусные инфекции
- Вирусные заболевания
- Инфекции
- Инфекции, передающиеся через кровь
- Передающиеся заболевания
- Заболевания, передающиеся половым путем, вирусные
- Заболевания, передающиеся половым путем
- Лентивирусные инфекции
- Ретровирусные инфекции
- Синдромы иммунологического дефицита
- Заболевания иммунной системы
- ВИЧ-инфекции
Другие идентификационные номера исследования
- 1100.1535
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .